Finally, we analyzed the CTNNB1 mutation profile in cfDNA in one patient with unresectable HCC with iso-high intensity in the hepatobiliary phase of EOB-MRI and three patients without HCC with iso-high intensity in the hepatobiliary phase of EOB-MRI who were treated with lenvatinib. Here, CTNNB1 is linked to hepatocellular carcinoma.